Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 1, 2006, Pages 293-298

  Ryder, John W ^a   Falcone, Julie F ^a   Manro, Jason R ^a   Svensson, Kjell A ^a   Merchant, Kalpana M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 4' [1 FLUORO 1 METHYL 2 (PROPANE 2 SULFONYLAMINO)ETHYL]BIPHENYL 4 CARBOXYLIC ACID METHYLAMIDE; ALKALOID; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; CYCLIC GMP; DIZOCILPINE; GLUTAMIC ACID; HARMALINE; LY 404187; LY 503430; N 2 [4 (4 CYANOPHENOL)PHENOL]PROPYL 2 PROPANESULFONAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CEREBELLUM; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; SHOCK;

ALLOSTERIC REGULATION; AMIDES; ANIMALS; BENZODIAZEPINES; BIPHENYL COMPOUNDS; CEREBELLUM; CYCLIC GMP; DIZOCILPINE MALEATE; MALE; MICE; RECEPTORS, AMPA; SULFONAMIDES; SYNAPTIC TRANSMISSION;

EID: 33748999038     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.105734     Document Type: Article

References (38)

1. Alt A, Nisenbaum ES, Bleakman D, and Witkin JM (2006) A role for AMPA receptors in mood disorders. Biol Pharmacol 71:1273-1288.
2. Alt A, Witkin JM, and Bleakman D (2005) AMPA receptor potentiators as novel antidepressants. Curr Pharm Des 11:1511-1527.
3. Arai A, Kessler M, Xiao P, Ambros-Ingerson J, Rogers G, and Lynch G (1994) A centrally active drug that modulates AMPA receptor gated currents. Brain Res 638:343-346.
4. Arai AC, Xia YF, Rogers G, Lynch G, and Kessler M (2002) Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action. J Pharmacol Exp Ther 303:1075-1085.
5. Barnstable CJ, Wei JY, and Han MH (2004) Modulation of synaptic function by cGMP and cGMP-gated cation channels. Neurochem Int 45:875-884.
6. Batini C, Buisseret-Delmas C, and Conrath-Verrier M (1979) Olivo-cerebellar activity during harmaline-induced tremor. A 2-[14C]deoxyglucose study. Neurosci Lett 12:241-246.
7. Biggio G and Guidotti A (1976) Climbing fiver activation and 3′,5′-cyclic guanosine monophosphate (cGMP) content in cortex and deep nuclei of cerebellum. Brain Res 107:365-373.
8. Black MD (2005) Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berl) 179:154-163.
9. Bleakman D, Ballyk BA, Schoepp DD, Palmer AJ, Bath CP, Sharpe EF, Woolley ML, Bufton HR, Kamboj RK, Tarnawa I, et al. (1996) Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles. Neuropharmacology 35:1689-1702.
10. Bleakman D and Lodge D (1998) Neuropharmacology of AMPA and kainate receptors. Neuropharmacology 37:1187-1204.
11. Borges K and Dingledine R (1998) AMPA receptors: molecular and functional diversity. Prog Brain Res 116:153-170.
12. Bredt DS and Snyder SH (1990) Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 87:682-685.
13. Calabresi P, Gubellini P, Centonze D, Sancesario G, Morello M, Giorgi M, Pisani A, and Bernardi G (1999) A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression. J Neurosci 19:2489-2499.
14. Danysz W (2002) CX-516 Cortex pharmaceuticals. Curr Opin Investig Drugs 3:1081-1088.
15. Desce JM, Godeheu G, Galli T, Artaud F, Cheramy A, and Glowinski J (1992) L-Glutamate-evoked release of dopamine from synaptosomes of the rat striatum: involvement of AMPA and N-methyl-D-aspartate receptors. Neuroscience 47:333-339.
16. Dinerman JL, Steiner JP, Dawson TM, Dawson V, and Snyder SH (1994) Cyclic nucleotide dependent phosphorylation of neuronal nitric oxide synthase inhibits catalytic activity. Neuropharmacology 33:1245-1251.
17. Dinnendahl V and Gumulka SW (1977) Stress-induced alterations of cyclic nucleotide levels in brain: effects of centrally acting drugs. Psychopharmacology (Berl) 52:243-249.
18. Fedele E and Raiteri M (1999) In vivo studies of the cerebral glutamate receptor/NO/cGMP pathway. Prog Neurobiol 58:89-120.
19. Gates M, Ogden A, and Bleakman D (2001) Pharmacological effects of AMPA receptor potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in vitro. Neuropharmacology 40:984-991.
20. Hollmann M and Heinemann S (1994) Cloned glutamate receptors. Annu Rev Neurosci 17:31-108.
21. Lamarre Y and Mercier LA (1971) Neurophysiological studies of harmaline-induced tremor in the cat. Can J Physiol Pharmacol 49:1049-1058.
22. Lei S, Jackson MF, Jia Z, Roder J, Bai D, Orser BA, and MacDonald JF (2000) Cyclic GMP-dependent feedback inhibition of AMPA receptors is independent of PKG. Nat Neurosci 3:559-565.
23. Llinas R and Volkind RA (1973) The olivo-cerebellar system: functional properties as revealed by harmaline-induced tremor. Exp Brain Res 18:69-87.
24. Lynch G (2004) AMPA receptor modulators as cognitive enhancers. Curr Opin Pharmacol 4:4-11.
25. Miki N, Kawabe Y, and Kuriyama K (1977) Activation of cerebral guanylate cyclase by nitric oxide. Biochem Biophys Res Commun 75:851-856.
26. Miu P, Jarvie KR, Radhakrishnan V, Gates MR, Ogden A, Ornstein PL, Zarrinmayeh H, Ho K, Peters D, Grabell J, et al. (2001) Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro. Neuropharmacology 40:976-983.
27. Murray TK, Whalley K, Robinson CS, Ward MA, Hicks CA, Lodge D, Vandergriff JL, Baumbarger P, Siuda E, Gates M, et al. (2003) LY503430, a novel α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J Pharmacol Exp Ther 306:752-762.
28. O'Neill MJ, Bleakman D, Zimmerman DM, and Nisenbaum ES (2004) AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord 3:181-194.
29. Ornstein PL, Zimmerman DM, Arnold MB, Bleisch TJ, Cantrell B, Simon R, Zarrinmayeh H, Baker SR, Gates M, Tizzano JP, et al. (2000) Biarylpropylsulfonamides as novel, potent potentiators of 2-amino-3-(5-methyl-3- hydroxyisoxazol-4-yl)-propanoic acid (AMPA) receptors. J Med Chem 43:4354-4358.
30. Parsons C, Danysz W, and Lodge D (2002) Introduction to glutamate receptors, their function and pharmacology, in Ionotropic Glutamate Receptors as Therapeutic Targets (Danysz W, Lodge D, and Parsons CG eds) pp. 1-30, F. P. Graham Publishing Co., Johnson City, TN.
31. Puzzo D, Vitolo O, Trinchese F, Jacob JP, Palmeri A, and Arancio O (2005) Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP- responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci 25:6887-6897.
32. Quirk JC and Nisenbaum ES (2002) LY404187: a novel positive allosteric modulator of AMPA receptors. CNS Drug Rev 8:255-282.
33. Raiteri M, Garrone B, and Pittaluga A (1992) N-Methyl-D-aspartic acid (NMDA) and non-NMDA receptors regulating hippocampal norepinephrine release. II. Evidence for functional cooperation and for coexistence on the same axon terminal. J Pharmacol Exp Ther 260:238-242.
34. Renno WM, Lee JH, and Beitz AJ (1997) Light and electron microscopic immunohistochemical localization of N-acetylaspartylglutamate (NAAG) in the olivocerebellar pathway of the rat. Synapse 26:140-154.
35. Vandergriff J, Huff K, Bond A, and Lodge D (2001) Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo. Neuropharmacology 40:1003-1009.
36. Wiklund L, Toggenburger G, and Cuenod M (1982) Aspartate: possible neurotransmitter in cerebellar climbing fibers. Science (Wash DC) 216:78-80.
37. Wood PL (1991) Pharmacology of the second messenger, cyclic guanosine 3′,5′-monophosphate, in the cerebellum. Pharmacol Rev 43:1-25.
38. Yamada KA (1998) Modulating excitatory synaptic neurotransmission: potential treatment for neurological disease? Neurobiol Dis 5:67-80.